See more : RTL Group S.A. (RTL.SW) Income Statement Analysis – Financial Results
Complete financial analysis of CorMedix Inc. (CRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CorMedix Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Golden Agri-Resources Ltd (E5H.SI) Income Statement Analysis – Financial Results
- Quilter plc (QLT.L) Income Statement Analysis – Financial Results
- Lingda Group Co., Ltd. (300125.SZ) Income Statement Analysis – Financial Results
- Edda Wind ASA (EWIND.OL) Income Statement Analysis – Financial Results
- Clearday, Inc. (CLRD) Income Statement Analysis – Financial Results
CorMedix Inc. (CRMD)
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 65.41K | 190.94K | 239.23K | 283.27K | 429.80K | 329.33K | 224.11K | 210.13K | 189.27K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 205.56K | 3.73K | 148.94K | 204.85K | 373.23K | 396.79K | 114.96K | 366.67K | 318.72K | 445.80K | 201.61K | 0.00 | 0.00 | 0.00 | 0.00 | 1.04M |
| Gross Profit | -205.56K | 61.67K | 42.00K | 34.39K | -89.97K | 33.01K | 214.36K | -142.57K | -108.59K | -256.53K | -199.60K | 0.00 | 0.00 | 0.00 | 0.00 | -1.04M |
| Gross Profit Ratio | 0.00% | 94.29% | 22.00% | 14.37% | -31.76% | 7.68% | 65.09% | -63.62% | -51.68% | -135.53% | -9,975.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.16M | 10.68M | 13.13M | 13.38M | 11.05M | 18.82M | 24.49M | 15.74M | 6.28M | 1.32M | 1.23M | 1.19M | 4.10M | 5.49M | 4.89M | 3.08M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.07M | 8.65M | 8.88M | 10.26M | 7.33M | 3.49M | 1.86M | 3.15M | 3.01M | 1.17M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.80M | 20.01M | 16.35M | 13.88M | 9.87M | 8.07M | 8.65M | 8.88M | 10.26M | 7.33M | 3.49M | 1.86M | 3.15M | 3.01M | 1.17M | 691.89K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.96M | 30.69M | 29.48M | 27.26M | 20.92M | 26.90M | 33.14M | 24.62M | 16.55M | 8.65M | 4.72M | 3.04M | 7.25M | 8.51M | 6.06M | 3.77M |
| Cost & Expenses | 48.96M | 30.69M | 29.48M | 27.46M | 21.29M | 27.29M | 33.25M | 24.99M | 16.86M | 9.09M | 4.92M | 3.04M | 7.25M | 8.51M | 6.06M | 4.82M |
| Interest Income | 0.00 | 326.02K | 14.40K | 116.07K | 322.67K | 36.62K | 110.71K | 126.77K | 60.39K | 2.71K | 668.00 | 1.97K | 12.04K | 23.44K | 2.13K | 25.90K |
| Interest Expense | 0.00 | 26.52K | 15.94K | 33.23K | 787.49K | 1.87K | 5.62K | 1.31K | 3.96K | 2.09K | 1.44M | 382.94K | 12.04K | 3.09M | 2.07M | 4.21M |
| Depreciation & Amortization | 70.76K | 209.04K | 177.02K | 143.49K | 73.29K | 74.22K | 36.89K | 25.60K | 15.08K | 15.07K | 5.16K | 7.02K | 12.25K | 12.17K | 9.95K | 1.04M |
| EBITDA | -48.89M | -30.05M | -29.38M | -27.02M | -20.63M | -26.75M | -32.97M | -24.62M | -18.17M | -20.44M | -7.68M | -3.04M | -7.19M | -8.47M | -6.04M | -3.75M |
| EBITDA Ratio | 0.00% | -46,321.48% | -15,421.12% | -11,329.92% | -7,302.40% | -6,241.92% | -9,963.77% | -10,980.81% | -7,889.64% | -4,693.90% | -245,581.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -48.96M | -30.62M | -29.44M | -27.22M | -21.01M | -26.86M | -32.92M | -24.76M | -16.65M | -8.90M | -4.92M | -3.04M | -7.25M | -8.51M | -6.06M | -4.82M |
| Operating Income Ratio | 0.00% | -46,819.91% | -15,417.51% | -11,378.44% | -7,416.31% | -6,250.44% | -9,997.39% | -11,048.80% | -7,925.56% | -4,703.30% | -245,646.93% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.62M | 336.65K | -22.83K | 23.67K | -485.98K | 34.57K | -85.80K | 117.29K | -1.53M | -11.55M | -4.22M | -380.97K | 41.86K | -2.68M | -2.07M | -4.18M |
| Income Before Tax | -46.34M | -30.29M | -29.46M | -27.20M | -21.49M | -26.83M | -33.01M | -24.64M | -18.19M | -20.45M | -9.13M | -3.43M | -7.21M | -11.19M | -8.12M | -9.00M |
| Income Before Tax Ratio | 0.00% | -46,305.23% | -15,429.47% | -11,368.54% | -7,587.87% | -6,242.40% | -10,023.45% | -10,996.46% | -8,655.37% | -10,806.25% | -456,426.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -585.62K | -1.25M | -5.17M | -5.06M | 36.44K | -31.27K | 1.31K | 3.96K | 2.09K | 1.44M | 1.97K | -493.86K | -280.92K | 2.13K | 0.00 |
| Net Income | -46.34M | -29.70M | -28.21M | -22.03M | -16.43M | -26.83M | -33.01M | -24.64M | -18.19M | -20.45M | -9.13M | -3.43M | -6.71M | -10.91M | -8.12M | -9.00M |
| Net Income Ratio | 0.00% | -45,409.90% | -14,774.70% | -9,207.70% | -5,801.29% | -6,242.40% | -10,023.45% | -10,996.46% | -8,655.37% | -10,806.25% | -456,426.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.91 | -0.74 | -0.75 | -0.77 | -0.68 | -1.51 | -2.99 | -3.25 | -2.90 | -4.77 | -3.30 | -1.50 | -2.94 | -5.76 | -47.40 | -3.94 |
| EPS Diluted | -0.91 | -0.74 | -0.75 | -0.77 | -0.68 | -1.51 | -2.99 | -3.25 | -2.90 | -4.77 | -3.30 | -1.50 | -2.94 | -5.76 | -47.40 | -3.94 |
| Weighted Avg Shares Out | 50.90M | 40.14M | 37.61M | 28.56M | 24.15M | 17.82M | 11.03M | 7.59M | 6.27M | 4.29M | 2.76M | 2.28M | 2.28M | 1.89M | 171.33K | 2.28M |
| Weighted Avg Shares Out (Dil) | 50.90M | 40.27M | 37.67M | 28.56M | 24.15M | 17.82M | 11.03M | 7.59M | 6.27M | 4.29M | 2.76M | 2.28M | 2.28M | 1.89M | 171.33K | 2.28M |
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products
BERKELEY HEIGHTS, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today highlights key policy changes from CMS that benefit hemodialysis patients. Yesterday,...
CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock?
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for November 8th
CRMD, FFIC and SPPJY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 8, 2024.
Stock Picks From Seeking Alpha's October 2024 New Analysts
In October, 42 new analysts joined Seeking Alpha, sharing diverse investment ideas and strategies, from biotech to real estate. Highlighted strong buy recommendations include MicroStrategy, CorMedix, Hewlett Packard Enterprise, Vertex Pharmaceuticals, and several others. Readers are encouraged to engage with...
New Strong Buy Stocks for November 8th
SPPJY, FFIC, CRMD, NTGR and AACAY have been added to the Zacks Rank #1 (Strong Buy) List on November 8, 2024.
Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High?
The consensus price target hints at a 52.2% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium
BERKELEY HEIGHTS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the Truist Securities BioPharma...
CorMedix Inc. (CRMD) Q3 2024 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q3 2024 Earnings Call October 30, 2024 8:30 AM ET Company Participants Dan Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Beth Zelnick Kaufman...
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
CorMedix (CRMD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.
CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update
‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J.
Source: https://incomestatements.info
Category: Stock Reports